U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H29NO10
Molecular Weight 527.5209
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DAUNORUBICIN

SMILES

C[C@@]1([H])[C@]([H])([C@]([H])(C[C@@]([H])(O1)O[C@@]2([H])C[C@@](Cc3c2c(c4c(C(=O)c5cccc(c5C4=O)OC)c3O)O)(C(=O)C)O)N)O

InChI

InChIKey=STQGQHZAVUOBTE-VGBVRHCVSA-N
InChI=1S/C27H29NO10/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3/t10-,14-,16-,17-,22+,27-/m0/s1

HIDE SMILES / InChI

Molecular Formula C27H29NO10
Molecular Weight 527.5209
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: https://www.ncbi.nlm.nih.gov/pubmed/22260166 | https://www.ncbi.nlm.nih.gov/pubmed/7932544 | https://www.ncbi.nlm.nih.gov/pubmed/13146115 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050467s070lbl.pdf

Daunorubicin, also known as daunomycin, is a chemotherapy medication used to treat cancer. Specifically, it is used for acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and Kaposi's sarcoma. Similar to doxorubicin, daunorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis. This inhibits the progression of the enzyme topoisomerase II, which relaxes supercoils in DNA for transcription. Daunorubicin stabilizes the topoisomerase II complex after it has broken the DNA chain for replication, preventing the DNA double helix from being resealed and thereby stopping the process of replication. On binding to DNA, daunomycin intercalates, with its daunosamine residue directed toward the minor groove. It has the highest preference for two adjacent G/C base pairs flanked on the 5' side by an A/T base pair. Daunorubicin should only be administered in a rapid intravenous infusion. It should not be administered intramuscularly or subcutaneously, since it may cause extensive tissue necrosis. It should also never be administered intrathecally (into the spinal canal), as this will cause extensive damage to the nervous system and may lead to death.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CERUBIDINE

Approved Use

Daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.

Launch Date

314409600000
Primary
CERUBIDINE

Approved Use

Daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.

Launch Date

314409600000
Primary
CERUBIDINE

Approved Use

Daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.

Launch Date

314409600000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
26 μg/mL
44 mg/m² 1 times / 2 days multiple, intravenous
dose: 44 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: Cytarabine
DAUNORUBICIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
637 μg × h/mL
44 mg/m² 1 times / 2 days multiple, intravenous
dose: 44 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: Cytarabine
DAUNORUBICIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
31.5 h
44 mg/m² 1 times / 2 days multiple, intravenous
dose: 44 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: Cytarabine
DAUNORUBICIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
3%
DAUNORUBICIN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
190 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 190 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 190 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 10
Health Status: unhealthy
Age Group: 10
Sex: M+F
Sources:
DLT: Neutropenia, Leucopenia...
Dose limiting toxicities:
Neutropenia (grade 4, 100%)
Leucopenia (grade 4, 100%)
Thrombocytopenia (grade 4, 16.7%)
Anemia (grade 4, 16.7%)
Sources:
155 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 155 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 155 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 10
Health Status: unhealthy
Age Group: 10
Sex: M+F
Sources:
DLT: Neutropenia, Leucopenia...
Disc. AE: Cardiac failure...
Dose limiting toxicities:
Neutropenia (grade 4, 100%)
Leucopenia (grade 4, 50%)
AEs leading to
discontinuation/dose reduction:
Cardiac failure (grade 5, 16.7%)
Sources:
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources:
unhealthy, 27-87
Health Status: unhealthy
Age Group: 27-87
Sex: M+F
Sources:
Disc. AE: Skin toxicity...
AEs leading to
discontinuation/dose reduction:
Skin toxicity (4.2%)
Sources:
20 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 20 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 20 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, 38.7
Health Status: unhealthy
Age Group: 38.7
Sex: M+F
Sources:
Disc. AE: Skin eruption...
AEs leading to
discontinuation/dose reduction:
Skin eruption (0.9%)
Sources:
80 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 80 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 80 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 60
Health Status: unhealthy
Age Group: 60
Sex: M+F
Sources:
100 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 60
Health Status: unhealthy
Age Group: 60
Sex: M+F
Sources:
DLT: Acute diverticular perforation...
Dose limiting toxicities:
Acute diverticular perforation
Sources:
100 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
Disc. AE: Ejection fraction decreased, Prolonged neutropenia...
Other AEs: Granulocytopenia, Thrombocytopenia...
AEs leading to
discontinuation/dose reduction:
Ejection fraction decreased (5.3%)
Prolonged neutropenia (2.6%)
Other AEs:
Granulocytopenia (grade 4, 21%)
Thrombocytopenia (grade 4, 8%)
Febrile neutropenia (grade 4, 11%)
Sources:
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources:
unhealthy
Disc. AE: Infusion related reaction, Myelosuppression...
AEs leading to
discontinuation/dose reduction:
Infusion related reaction (acute)
Myelosuppression (severe)
Cardiotoxicity
Congestive heart failure
Hepatic impairment
Reaction anaphylactic anaphylactoid (grade 3-5)
Sources:
AEs

AEs

AESignificanceDosePopulation
Leucopenia grade 4, 100%
DLT
190 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 190 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 190 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 10
Health Status: unhealthy
Age Group: 10
Sex: M+F
Sources:
Neutropenia grade 4, 100%
DLT
190 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 190 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 190 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 10
Health Status: unhealthy
Age Group: 10
Sex: M+F
Sources:
Anemia grade 4, 16.7%
DLT
190 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 190 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 190 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 10
Health Status: unhealthy
Age Group: 10
Sex: M+F
Sources:
Thrombocytopenia grade 4, 16.7%
DLT
190 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 190 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 190 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 10
Health Status: unhealthy
Age Group: 10
Sex: M+F
Sources:
Neutropenia grade 4, 100%
DLT
155 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 155 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 155 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 10
Health Status: unhealthy
Age Group: 10
Sex: M+F
Sources:
Leucopenia grade 4, 50%
DLT
155 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 155 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 155 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 10
Health Status: unhealthy
Age Group: 10
Sex: M+F
Sources:
Cardiac failure grade 5, 16.7%
Disc. AE
155 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 155 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 155 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 10
Health Status: unhealthy
Age Group: 10
Sex: M+F
Sources:
Skin toxicity 4.2%
Disc. AE
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources:
unhealthy, 27-87
Health Status: unhealthy
Age Group: 27-87
Sex: M+F
Sources:
Skin eruption 0.9%
Disc. AE
20 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 20 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 20 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, 38.7
Health Status: unhealthy
Age Group: 38.7
Sex: M+F
Sources:
Acute diverticular perforation DLT, Disc. AE
100 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 60
Health Status: unhealthy
Age Group: 60
Sex: M+F
Sources:
Prolonged neutropenia 2.6%
Disc. AE
100 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
Ejection fraction decreased 5.3%
Disc. AE
100 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
Febrile neutropenia grade 4, 11%
100 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
Granulocytopenia grade 4, 21%
100 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
Thrombocytopenia grade 4, 8%
100 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
Cardiotoxicity Disc. AE
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources:
unhealthy
Congestive heart failure Disc. AE
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources:
unhealthy
Hepatic impairment Disc. AE
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources:
unhealthy
Infusion related reaction acute
Disc. AE
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources:
unhealthy
Reaction anaphylactic anaphylactoid grade 3-5
Disc. AE
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources:
unhealthy
Myelosuppression severe
Disc. AE
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources:
unhealthy
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [IC50 203 uM]
yes [Ki 49.4 uM]
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
PubMed

PubMed

TitleDatePubMed
Myocardial injury produced by antineoplastic drugs.
1975
The cardiotoxicity of adriamycin and daunomycin in children.
1976 Feb
Tumorigenicity in vivo and induction of malignant transformation and mutagenesis in cell cultures by adriamycin and daunomycin.
1976 Jun
Daunorubicin-induced cardiotoxicity.
1976 Mar
HIV-1 and HIV-2 reverse transcriptases: a comparative study of sensitivity to inhibition by selected natural products.
1992 May 29
Bradycardia due to anthracyclines.
1992 Oct 3
NTPase/helicase of Flaviviridae: inhibitors and inhibition of the enzyme.
2002
Effect of aging on cardiac contractility in a rat model of chronic daunorubicin cardiotoxicity.
2002
Correlation of histopathological and biochemical appraisal of anthracyclin-induced myocardium damage.
2002
Effects of dietary lipids on daunomycin-induced nephropathy in mice: comparison between cod liver oil and soybean oil.
2002 Apr
Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia.
2002 Aug
Subcellular daunorubicin distribution and its relation to multidrug resistance phenotype in drug-resistant cell line SMMC-7721/R.
2002 Aug
Reversible vincristine-related flaccid paralysis in a child with acute lymphoblastic leukemia.
2002 Aug
Reversal of multidrug resistance-associated protein-mediated daunorubicin resistance by camptothecin.
2002 Aug
Comparative study of chronic toxic effects of daunorubicin and doxorubicin in rabbits.
2002 Dec
Comparison of anthracycline-induced death of human leukemia cells: programmed cell death versus necrosis.
2002 Dec
Determination of free and liposome-associated daunorubicin and daunorubicinol in plasma by capillary electrophoresis.
2002 Dec 6
A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer.
2002 Jul 1
[Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].
2002 Jul-Aug
Monitoring daunorubicin-induced alterations in protein expression in pancreas carcinoma cells by two-dimensional gel electrophoresis.
2002 Jun
Influence of chemosensitizers on resistance mechanisms in daunorubicin-resistant Ehrlich ascites tumour cells.
2002 Jun
Homocamptothecin-daunorubicin association overcomes multidrug-resistance in breast cancer MCF7 cells.
2002 May
Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myeloma. A phase II International Oncology Study Group study.
2002 May 15
Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells.
2002 Nov
Resistance of bcr-abl-positive acute lymphoblastic leukemia to daunorubicin is not mediated by mdr1 gene expression.
2002 Nov
Nucleotide triphosphatase/helicase of hepatitis C virus as a target for antiviral therapy.
2002 Sep
Liposomal daunorubicin (DaunoXome) for treatment of relapsed meningeal acute myeloid leukemia.
2002 Sep
Induction of metallothionein by zinc protects from daunorubicin toxicity in rats.
2002 Sep 30
High-dose daunorubicin as liposomal compound (Daunoxome) in elderly patients with acute lymphoblastic leukemia.
2003
Multiple alterations of canalicular membrane transport activities in rats with CCl(4)-induced hepatic injury.
2003 Apr
A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia.
2003 Apr
Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients.
2003 Dec 1
Different effects of metabolic inhibitors and cyclosporin A on daunorubicin transport in leukemia cells from patients with AML.
2003 Feb
Effects of carvedilol on MDR1-mediated multidrug resistance: comparison with verapamil.
2003 Jan
Vincristine neurotoxicity in the presence of hereditary neuropathy.
2003 Jan
Safety of high-dose liposomal daunorubicin (daunoxome) for refractory or relapsed acute myeloblastic leukaemia.
2003 Jul
Cytotoxic drugs enhance the ex vivo sensitivity of malignant cells from a subset of acute myeloid leukaemia patients to apoptosis induction by tumour necrosis factor receptor-related apoptosis-inducing ligand.
2003 Jun
Daunorubicin-induced variations in gene transcription: commitment to proliferation arrest, senescence and apoptosis.
2003 Jun 15
The dose related effect of steroids on blast reduction rate and event free survival in children with acute lymphoblastic leukemia.
2003 Mar
Efficacy and toxicity of liposomal daunorubicin included in PVABEC regimen for aggressive NHL of the elderly.
2003 Mar
[Successful treatment after acute promyelocytic leukemia (APL) syndrome of relapsed API with arsenic trioxide].
2003 Mar
Cloning and functional characterization of the multidrug resistance-associated protein (MRP1/ABCC1) from the cynomolgus monkey.
2003 Mar
From conventional to stealth liposomes: a new frontier in cancer chemotherapy.
2003 May-Jun
Cardiac troponin T as an indicator of reduced left ventricular contractility in experimental anthracycline-induced cardiomyopathy.
2003 Nov
Liposomal daunorubicin (DaunoXome) in multiple myeloma: a modified VAD regimen using short-term infusion.
2003 Nov
Neurotoxicity of intrathecal methotrexate: MR imaging findings.
2003 Oct
Population pharmacokinetics of liposomal daunorubicin in children.
2003 Oct
Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia.
2003 Oct
Potentiation of tumour apoptosis by human growth hormone via glutathione production and decreased NF-kappaB activity.
2003 Sep 15
Human intestinal absorption of imidacloprid with Caco-2 cells as enterocyte model.
2004 Jan 1
Patents

Sample Use Guides

Usual Adult Dose for Acute Nonlymphocytic Leukemia: Under 60 years of age: 45 mg/m2 IV over 2 to 5 minutes once a day on days 1, 2, and 3 for the first course and on days 1 and 2 for subsequent courses) with cytosine arabinoside (ara-C) intravenously once a day (usually for 7 days for the first course and 5 days for subsequent courses) as remission induction therapy.
Route of Administration: Intravenous
In order to determine the viability of HL-60, K562, THP-1, and HEK293T cells, they were trypsinized, counted, and seeded into 96-well plates and were treated with serial dilutions (0.0001, 0.001, 0.01, 0.1, 1 mkM) of DNR (Daunorubicin). Cell viability was determined 48 h after DNR treatment using the luminescent cell viability assay (Promega) through luminescence testing by BMG NOVOstar machine.
Substance Class Chemical
Created
by admin
on Sat Jun 26 03:05:26 UTC 2021
Edited
by admin
on Sat Jun 26 03:05:26 UTC 2021
Record UNII
ZS7284E0ZP
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DAUNORUBICIN
HSDB   INN   MART.   MI   VANDF   WHO-DD  
INN  
Official Name English
FI 6339
Code English
RP 13057
Code English
EPIRUBICIN IMPURITY D
Common Name English
DAUNORUBICIN [MI]
Common Name English
(8S,10S)-8-ACETYL-10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-6,8,11-TRIHYDROXY-1-METHOXY-7,8,9,10-TETRAHYDROTETRACENE-5,12-DIONE
Common Name English
DAUNORUBICIN [HSDB]
Common Name English
VYXEOS COMPONENT DAUNORUBICIN
Brand Name English
RP-13057
Code English
5,12-NAPHTHACENEDIONE, 8-ACETYL-10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL))OXY)-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-1-METHOXY-, (8S-CIS)-
Common Name English
DAUNOMYCIN
Common Name English
VALRUBICIN IMPURITY, DAUNORUBICIN [USP]
Common Name English
FI-6339
Code English
NSC-83142
Code English
EPIRUBICIN HYDROCHLORIDE IMPURITY D [EP]
Common Name English
DAUNORUBICIN [MART.]
Common Name English
EPIRUBICIN HYDROCHLORIDE IMPURITY, DAUNORUBICIN- [USP]
Common Name English
DAUNORUBICIN [WHO-DD]
Common Name English
(1S,3S)-3-ACETYL-1,2,3,4,6,11-HEXAHYDRO-3,5,12-TRIHYDROXY-10-METHOXY-6,11-DIOXO-1-NAPHTHACENYL 3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSIDE
Common Name English
DOXORUBICIN HYDROCHLORIDE IMPURITY A [EP]
Common Name English
DAUNORUBICIN [ORANGE BOOK]
Common Name English
DAUNORUBICIN [VANDF]
Common Name English
DAUNORUBICIN [INN]
Common Name English
DAUNOMYCIN [IARC]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175414
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
NCI_THESAURUS C1594
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
FDA ORPHAN DRUG 265808
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
WHO-ATC L01DB02
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
NDF-RT N0000007530
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 8.2
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
WHO-ATC L01XY01
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
NDF-RT N0000000176
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
NDF-RT N0000007530
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
LIVERTOX 270
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
NDF-RT N0000007530
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
EU-Orphan Drug EU/3/11/942
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
WHO-VATC QL01DB02
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
Code System Code Type Description
HSDB
5095
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
PRIMARY
INN
2257
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
PRIMARY
EVMPD
SUB06917MIG
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
PRIMARY
WIKIPEDIA
DAUNORUBICIN
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
PRIMARY
ChEMBL
CHEMBL178
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
PRIMARY
DRUG BANK
DB00694
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
PRIMARY
PUBCHEM
30323
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
PRIMARY
EPA CompTox
20830-81-3
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
PRIMARY
NCI_THESAURUS
C62091
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
PRIMARY
MESH
D003630
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
PRIMARY
IUPHAR
7063
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
PRIMARY
MERCK INDEX
M4104
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
PRIMARY Merck Index
FDA UNII
ZS7284E0ZP
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
PRIMARY
CAS
20830-81-3
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
PRIMARY
RXCUI
3109
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
PRIMARY RxNorm
DRUG CENTRAL
786
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
PRIMARY
ECHA (EC/EINECS)
244-069-7
Created by admin on Sat Jun 26 03:05:27 UTC 2021 , Edited by admin on Sat Jun 26 03:05:27 UTC 2021
PRIMARY
Related Record Type Details
TRANSPORTER -> SUBSTRATE
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> INHIBITOR
Related Record Type Details
METABOLITE -> PARENT
MAJOR
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC